BI 1015550

Phase 2
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type

Drug Detail

BI 1015550 is under development for patients with IPF

Study Purpose

To investigate the efficacy of BI 1015550 compared to placebo based on the change from baseline in Forced Vital Capacity (FVC).

To investigate safety and tolerability of BI 1015550 in the overall trial population.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >